CTA
TECH icon

Carillon Tower Advisers’s Bio-Techne TECH Stock Holding History

Carillon Tower Advisers’s Portfolio TECH Stock Details TECH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3,320
Closed -$125K – 503
2018
Q1 		$125K Sell
3,320
-10,800
-76% -$382K ﹤0.01% 454
2017
Q4 		$437 Buy
+14,120
New +$449K ﹤0.01% 293

Other funds holding TECH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Carillon Tower Advisers's TECH Position: Q2 2018 in Review

Carillon Tower Advisers sold out of Bio-Techne (TECH) in Q2 2018, closing a stake of 3,320 shares — an estimated $125K sold.

Carillon Tower Advisers first reported a position in TECH in Q4 2017 and held it in 2 quarters. The position peaked at $125K in Q1 2018. 341 funds tracked by Wall St. Rank hold TECH as of Q2 2018.

  • Carillon Tower Advisers reported no remaining Bio-Techne position as of Q2 2018 after selling out during the quarter.
  • Carillon Tower Advisers sold 3,320 Bio-Techne shares in Q2 2018, an estimated $125K.
  • Carillon Tower Advisers first reported a position in Bio-Techne in Q4 2017 and held it in 2 quarters.
  • Carillon Tower Advisers's Bio-Techne position peaked at $125K in Q1 2018.
  • 341 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2018.

Based on Carillon Tower Advisers's 13F filing for Q2 2018, filed 9 Aug 2018.